MIM
CABA icon

MetLife Investment Management’s Cabaletta Bio CABA Stock Holding History

MetLife Investment Management’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,714
Closed -$131K – 2820
2024
Q3 		$131K Hold
27,714
– – ﹤0.01% 2514
2024
Q2 		$207K Buy
27,714
+9,399
+51% +$115K ﹤0.01% 2222
2024
Q1 		$312K Hold
18,315
– – ﹤0.01% 1938
2023
Q4 		$416K Hold
18,315
– – ﹤0.01% 1804
2023
Q3 		$279K Buy
18,315
+4,746
+35% +$64.9K ﹤0.01% 2002
2023
Q2 		$175K Buy
+13,569
New +$147K ﹤0.01% 2362

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's CABA Position: Q4 2024 in Review

MetLife Investment Management sold out of Cabaletta Bio (CABA) in Q4 2024, closing a stake of 27,714 shares — an estimated $131K sold.

MetLife Investment Management first reported a position in CABA in Q2 2023 and held it in 6 quarters. The position peaked at $416K in Q4 2023. 108 funds tracked by Wall St. Rank hold CABA as of Q4 2024.

  • MetLife Investment Management reported no remaining Cabaletta Bio position as of Q4 2024 after selling out during the quarter.
  • MetLife Investment Management sold 27,714 Cabaletta Bio shares in Q4 2024, an estimated $131K.
  • MetLife Investment Management first reported a position in Cabaletta Bio in Q2 2023 and held it in 6 quarters.
  • MetLife Investment Management's Cabaletta Bio position peaked at $416K in Q4 2023.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.